SCHEMBL689019

SCHEMBL689019

Clc1ccc(OCCBr)cc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 4/20 0.52
DRD2 P14416 3/20 0.48
DRD3 P35462 3/20 0.48
KCNH2 Q12809 2/20 0.48
ALDH3A1 P30838 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAOB P27338 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
LTA4H P09960 1/20 0.46
PTGS2 P35354 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HRH3 Q9Y5N1 5/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4754349 0.88 DRD4 (0.55) DRD4DRD2DRD3KCNH2ALDH3A1
SCHEMBL14832975 0.88 DRD4 (0.44) DRD4DRD2DRD3KCNH2ALDH3A1
SCHEMBL8140756 0.87 NPC1 (0.47) NPC1RAB9ASMN1; SMN2LTA4H
SCHEMBL1172364 0.86 DRD4 (0.53) DRD4DRD2DRD3KCNH2ALDH3A1
SCHEMBL1345118 0.85 MAOB (0.57) DRD4DRD2DRD3KCNH2ALDH3A1
SCHEMBL7621718 0.85 HRH3 (0.53) DRD4DRD2DRD3KCNH2ALDH3A1
SCHEMBL10384122 0.85 HRH3 (0.53) DRD4DRD2DRD3KCNH2ALDH3A1
SCHEMBL6752147 0.85 HRH3 (0.53) DRD4DRD2DRD3KCNH2ALDH3A1
SCHEMBL7390013 0.85 HRH3 (0.53) DRD4DRD2DRD3KCNH2ALDH3A1
SCHEMBL10732157 0.83 LTA4H (0.53) DRD4DRD2DRD3KCNH2ALDH3A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117105872-B Benzodiazepine compound and preparation method and application thereof 徐州医科大学 2024-10-15 CN claimed
CN-117105872-A Benzodiazepine compound and preparation method and application thereof 徐州医科大学 2023-11-24 CN claimed
EP-1420021-A1 DNA Methyltransferase inhibitors The Penn State Research Foundation (US) 2004-05-19 EP claimed
JP-2003501431-A 2003-01-14 JP claimed
EP-1181291-A2 DNA METHYLTRANSFERASE INHIBITORS THE PENN STATE RESEARCH FOUNDATION (US) 2002-02-27 EP claimed
WO-2000075142-A2 DNA METHYLTRANSFERASE INHIBITORS THE PENN STATE RESEARCH FOUNDATION (US) 2000-12-14 WO claimed
US-4554356-A Method for production of imidazolyl vinyl ethers SIEGFRIED AKTIENGESELLSCHAFT (CH) 1985-11-19 US claimed
EP-3233077-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2026-05-06 EP disclosed
US-12428373-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2025-09-30 US disclosed
WO-2025024563-A2 CAP ANALOGS AND METHODS OF USE THEREOF TRILINK BIOTECHNOLOGIES, LLC (US) 2025-01-30 WO disclosed
CN-117105872-B Benzodiazepine compound and preparation method and application thereof 徐州医科大学 2024-10-15 CN disclosed
US-20240189304-A1 BET PROTEIN INHIBITORS AND USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-13 US disclosed
CN-118164914-A Indazole compound and synthetic method and application thereof 华东师范大学 2024-06-11 CN disclosed
EP-0034894-A2 2-(1-Piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives, processes for their preparation, intermediates used in the processes and the preparation thereof and pharmaceutical compositions containing the derivatives AYERST, MCKENNA AND HARRISON INC. (CA) 1981-09-02 EP disclosed
US-4268507-A Monophosphonate compounds as hypoglycemic and/or antiartherogenic agents SYMPHAR S.A. (CH) 1981-05-19 US disclosed
EP-0016310-A1 Monophosphonate compounds, process for their preparation and pharmaceutical compositions containing them SYMPHAR S.A. (CH) 1980-10-01 EP disclosed
US-4210657-A FUNGICIDES, BACTERICIDES SIEGFRIED AKTIENGESELLSCHAFT (CH) 1980-07-01 US disclosed
EP-0008804-A1 Imidazolylvinylethers, their preparation and application as active agent in pharmaceutical and biocidal compositions SIEGFRIED AKTIENGESELLSCHAFT (CH) 1980-03-19 EP disclosed
US-4017631-A MICROBIOCIDES JANSSEN PHARMACEUTICA N.V. (BE) 1977-04-12 US disclosed
US-3991202-A ANTIMICROBIALS JANSSEN PHARMACEUTICA N.V. (BE) 1976-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428373-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 DRD4 12/4885DRD2 1/4885DRD3 4/4885
US-20240189304-A1 BET PROTEIN INHIBITORS AND USE THEREOF BET1, BRD4, BRPF3 DRD4 4349/4885DRD2 4194/4885DRD3 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.